Thrombosis |
From the Departments of Hematology (J.J.Z., J.J.S.) and Pulmonary Diseases (H.I.G.T., J.-W.J.L., L.K., P.H.M.K.), University Hospital Utrecht, Netherlands
Correspondence to J.J. Zwaginga, MD, PhD, Department of Hematology, University Hospital Utrecht, Heidelberglaan 100, PO BOX 85500, 3584 CX, Utrecht, the Netherlands. E-mail J.J.Zwaginga{at}digd.azu.nl
| Abstract |
|---|
|
|
|---|
Key Words: platelet adhesiveness thrombosis pathophysiology vascular injury leukocyte adhesion flow
| Introduction |
|---|
|
|
|---|
Up to now, platelet-dependent PMN adherence was studied at surfaces that were almost completely covered with spread platelets. Normal platelet adhesion, however, varies not only in extent of coverage, but also in morphology. Initial platelet adhesion is characterized by often reversible adhesion of spherical (contact) platelets that readily spread out on the surface. The formation of platelet aggregates is a strong indicator of platelet activation and is regulated not only by the protein composition of the subendothelial tissue but also by local stimuli such as coagulation-dependent thrombin and platelet-secreted stimuli.14 The influence of platelet coverage, platelet adhesion morphology, and the related activation state of these platelets on PMN adhesion is unknown and is the subject of our study. We hypothesized that an increase in platelet coverage and aggregate formation or activation would enhance platelet-dependent PMN adhesion. Surprisingly, our results seem to indicate that even a low coverage of nonaggregated platelets ensures optimal leukocyte adhesion.
| Methods |
|---|
|
|
|---|
Vessel Wall Models and Perfusion Surfaces
All cells were of human origin. Human umbilical vein
endothelial cells (HUVECs) were isolated from human
umbilical cord veins15 with minor
modifications.16 Endothelial cells of the
second passage were harvested by trypsin digestion and subcultured on
formaldehyde (0.5%)-fixed gelatin (1%)-coated glass coverslips.
Smooth muscle cells (SMCs) were isolated from human umbilical arteries
as described before.17 Fibroblasts were isolated from
pulmonary arteries.18 The HUVECs and SMCs were
cultured in RPMI 1640 containing penicillin, streptomycin, and
amphotericin B with 20% (vol/vol) heat-inactivated normal
human serum. The medium for fibroblasts contained 10% pooled bovine
serum instead. HUVECs reached confluence in 5 to 7 days. SMCs and
fibroblasts reached confluence within 5 to 12 days.
Endothelial cell matrix (ECM), fibroblast matrix (FbM), and smooth muscle cell matrix (SMCM) were isolated by removing the confluent cells by treatment with 0.1 mol/L NH4OH (5 to 15 minutes at room temperature) and subsequently keeping the treated matrices in PBS at 4°C for a maximum of 2 to 3 weeks.
Fibrinogen was coated on gelatin-coated glass coverslips (1% wt/wt gelatin in PBS, 10 minutes at room temperature) by incubation with fibrinogen (1 mg/mL) in PBS for 30 minutes at room temperature.
Collagen (1 mg/mL) was coated the day before use with the aid of a retouching air brush at a nitrogen pressure of 1 atm.19 The collagen was sprayed at a density of approximately 30 µg/cm.2
Fibronectin was purified as described by Houdijk et al,20 coated on gelatin-coated glass coverslips by incubation with fibronectin (Fn; 100 µg/mL) in PBS, and used the same day. All coated coverslips were blocked for specific binding with a 1% human albumin solution in PBS.
Neutrophil Isolation
Blood was obtained from healthy volunteers from the Blood Bank,
Utrecht, the Netherlands. Mixed granulocytes were purified
from the buffy coat of 500 mL, anticoagulated with 0.34% (wt/vol)
trisodium-citrate (pH 7.4) as described before.21 PMN
purity was >95% with a viability (trypan-blue exclusion method) of
>98%; PMN morphology was checked by light microscopy. Maximal allowed
presence of polarized aggregated cells was 1%. Isolated PMNs were
suspended in HEPES buffer at 2x106/mL and kept
at room temperature until the start of perfusion.
Perfusion Chamber and Set-Up
Perfusion with laminar nonpulsatile flow was performed in a
transparent rectangular perfusion chamber with a slit height of
0.3 mm and width of 6 mm. The chamber is a modification from
the original.20 The chamber holds 2 circular knobs on
which vessel wall model-containing coverslips can be mounted; in this
way the vessel walls are exposed to whole blood or leukocyte
suspensions. Perfusates were aspirated (neutrophils) or pumped
(whole blood) through silicone elastomer tubing and the perfusion
chamber at a precisely controlled flow. The wall shear stress (t) was
calculated from the Navier Stokes equation: t=(6
·
)/(W · h2). The shear rate is
proportional to the flow rate of the cells and is calculated in units
of pascals or dynes/cm2 (1 pascal is
approximately 10 dynes/cm2).
Perfusion with whole blood was performed as described
before20 to obtain uniform platelet adhesion on the
coverslips. In short, 15 mL of citrate (1:10 vol/vol 110 mmol/L
trisodium-citrate) -anticoagulated whole blood (prewarmed for 15
minutes at 37°C) from healthy donors was circulated for varying
periods between 2 and 10 minutes at a shear rate of 1600
s-1 in a roller pumpbased recirculating
system. In some control experiments, low-molecular-weight heparin
(Fragmin, Kabi Vitrum; 20 U/mL) was used to anticoagulate the whole
blood. However, overall results were not changed by heparin instead of
citrate anticoagulation. Control perfusions were performed with
platelet-poor plasma, which was obtained by
centrifugation of whole blood (10 minutes at
3000g, room temperature). To test the influence of
platelet inhibition, 30 µmol/L indomethacin
was added from a 14 mmol/L stock solution in ethanol (Sigma) to
whole blood perfusate at least 30 minutes before the start of
perfusion. Between experiments the system was thoroughly rinsed with
prewarmed HEPES buffer (20 mmol/L HEPES, 132 mmol/L NaCl,
6 mmol/L KCl, 1.2 mmol/L
KH2PO4, 1 mmol/L
MgSO4 · 7H2O, 5
mmol/L
-D-glucose, 1 mmol/L
CaCl2, pH 7.4) to remove blood remnants. After
perfusions, platelet-covered coverslips were removed and briefly
stored in HEPES for subsequent perfusion with PMN suspensions the same
day. Some coverslips were fixed (1% paraformaldehyde)
and stained with May-Grünwald/Giemsa to determine the percentage
of surface-covered platelets and their morphology. The coverage was
evaluated by light microscopy using an Quantimet 570 image
analysis system (Leica/Cambridge LTD).
Subsequently, prewarmed (5 minutes at 37°C) PMNs in suspension were aspirated through the perfusion chamber and over the platelet-covered surfaces with a syringe pump (Harvard Apparatus). To test additional stimulation of the surface-associated platelets, we incubated the coverslips with 1 U/mL thrombin (Sigma) in PBS for 5 minutes; afterward, coverslips were briefly rinsed and the remaining thrombin was blocked by 30 µmol/L D-Phe-Pro-Arg Chloro- methylketone (Bachem Feinchemikalien AG). During PMN perfusion, the flow chamber was mounted on a microscope stage (DM RXE; Leica) equipped with a black and white CCD-video camera (Sanyo) coupled to a VHS video recorder. Perfusion experiments were recorded on videotape.3
Image Processing
Video images were evaluated for the number of adherent cells and
the (rolling) velocity per cell with a Quantimet 570C
image-analysis system (Leica). The number of surface-adherent
neutrophils was measured after 5 minutes of perfusion in a minimum of
30 randomized high-power fields (total surface >3
mm2). The rolling velocity of cells was measured
as described previously.3 In short, a sequence of images
was digitally captured with a preset interval (
t). At each image,
positions of individual cells were detected. The velocity was
calculated from the total distance traveled by each cell and the time
(amount of images x
t). The cutoff value to distinguish between
rolling and static adhesion was set at 1 µm/s. With this method
total PMN adhesion (static adherent+rolling cells) and percentage
rolling cells (rolling adhesion/total adhesion x100%) could be
calculated. Freely flowingnot adherentcells were not in focus and
therefore not included in the automated evaluation.
Statistical Analysis
Results are expressed as mean±SD. Statistical analysis
of the data were performed using a paired Student's t test
for single measurements, or repeated measures ANOVA for a series of
measurements.
| Results |
|---|
|
|
|---|
2 dynes/cm2) total
adhesion, percentage of rolling PMNs, and rolling velocity were
evaluated and correlated with the platelet coverage. The latter 2
parameters could only be measured at >15% platelet
coverage. Below this coverage, we observed PMNs to stick, roll, and
detach between the sparsely present platelets on the surface.
This "hopping" behavior, which can also be described as a sort of
tethering, interfered with the computer-assisted evaluation. Secondary
tethering (PMNs rolling over PMNs already associated with the surface,
leading to cluster formation) was also observed but was not different
under the various conditions.
PMN adhesion (Figure 1
) clearly
increases with platelet coverage of ECM (logarithmic fit with
coefficients y0=349, a1=230; R=0.73; P<0.01).
The PMN adhesion at platelet coverage >15% soon reaches a maximum
of 1000 to 1200 cells/mm2. In contrast with PMN
adhesion, PMN rolling velocity (Figure 2
)
decreased with increasing platelet coverage from 12 µm/s at
20% platelet coverage to 4 µm/s at 95% platelet
coverage (correlation coefficient, -0.63; P<0.01). This
decrease in rolling velocity underlines that greater selectin density
increases the possible interactions of PMNs with the
platelet-covered ECM. Although the percentage of PMNs that rolled
on platelets was less at 95% platelet coverage (12%) than at
20% platelet coverage (22%), no significant correlation between
both parameters was reached (correlation coefficient,
-0.08; P>0.1) (Figure 3
).
|
|
|
PMN Adherence to FbM and SMCM: Effect 0f Local Platelet
Presence
FbM and SMCM, as models for different depths of vessel wall
injury, were perfused with whole blood. ECM perfusions were included as
a control. To obtain comparable platelet coverage at the different
surfaces we perfused ECM for 2 minutes and FbM and SMCM both for 5
minutes. Subsequent PMN adhesion to these surfaces was studied in the
above-mentioned manner. Again, prior perfusion with platelet-poor
plasma was used to study the PMN adherence to ECM, FbM, and SMCM that
was not dependent on platelet presence.
Platelet adhesion at the surfaces was comparable in coverage
(approximately 30%) and morphology, consisting predominantly of spread
platelets and some small aggregates. Total PMN adhesion to the
platelet-covered surfaces showed large variations (600 to 1100
cells/mm2; Table 1
)
but no significant differences were observed. Platelet-covered FbM,
however, was more effective in slowing down PMNs (P<0.05)
and tended to be more effective in supporting total adhesion than ECM
with platelets. PMN adhesion to naked surfaces was <15% of the
PMN adhesion that was present at platelet-covered matrices,
indicating the clear dependency of PMN adhesion for surface-associated
platelets.
|
PMN Adhesion to Platelets at Purified Matrix Proteins
The protein composition of vessel wall models determines not
only the platelet coverage but also the activation and morphology
of the adhering platelets. We further tested whether specific
components of the vessel wall change platelet adhesion and
activation enough to also influence subsequent PMN adhesion.
Fibrinogen, collagen type III, and Fn were first exposed to whole blood
perfusion to obtain typical platelet adherence. Protein surfaces
without platelet adhesion were prepared by perfusing with
platelet-poor plasma.
On Fn, total platelet coverage was low (5%), even with longer (10
minutes) whole blood perfusion. On collagen and fibrinogen, however,
platelet coverage was comparable to that with ECM, and well above
15% platelet coverage in this sense was clearly surface-dependent.
Furthermore, platelet morphology differed considerably among the
surfaces. On ECM, Fn, and fibrinogen, spread platelets
predominated, whereas collagen induced clear formation of platelet
aggregates. Subsequent PMN adhesion to these platelet-covered
surfaces was evaluated and compared with adhesion to platelets on
ECM in parallel experiments (Table 2
).
|
In accordance with the results obtained for low platelet coverage on ECM, the low platelet coverage on Fn resulted in less PMN adhesion. Moreover, Fn itself without platelets showed less PMN adhesion than the other surfaces. The predominantly spread platelets on fibrinogen supported PMN adhesion equally as well as ECM with platelets. The aggregates on collagen did not affect PMN adhesion either. The rolling velocity and the percentage of PMN that rolled on collagen-, fibrinogen-, or ECM-associated platelets did not differ in these experiments. On Fn, the latter parameters could not be obtained because of low platelet coverage and low PMN adhesion.
PMN Adherence to Platelets With Different Morphology: Effect of
Additional Platelet Stimulation or Inhibition
Additional stimuli such as thrombin generated by the coagulation
pathway or stimuli secreted by activated platelets cause
platelet aggregate and thus thrombus formation. Most platelet
inhibitors are designed to inhibit platelet
aggregation. We investigated whether PMN adhesion was influenced by the
presence of platelet aggregates instead of spread platelets.
Moreover, we tested whether additional activation or inhibition of
surface-associated platelets changed the PMN adhesion. For this
purpose, collagen-coated coverslips were perfused with whole blood with
and without indomethacin. In this way normal
platelet aggregate formation at collagen surfaces was inhibited.
The normal platelet adhesion on ECM, consisting of predominantly
spread platelets, was used as a control. Additional stimulation of
surface-adherent platelets was obtained by thrombin (1 U/mL)
treatment. Platelet coverage on ECM and collagen was comparable
(approximately 60% to 70%); addition of indomethacin
to the perfusate or thrombin stimulation of the adherent
platelets did not change the amount of platelet coverage. On
collagen, the flow-oriented aggregate formation was adequately
inhibited by indomethacin (Figure 4
). The predominantly spread platelet
adhesion on ECM was minimally influenced by
indomethacin, but formation of small aggregates was
inhibited. Thrombin treatment flattened out the contact platelets
and aggregates present at both surfaces.
|
Notwithstanding the clear differences in platelet activation
and morphology induced by the surfaces and treatment with thrombin or
indomethacin, PMN adhesion (Table 3
; total adhesion, percentage rolling
cells, and rolling velocity) remained unchanged. Additionally, when the
flow-oriented platelet aggregates on collagen were turned
90-degrees perpendicular to the PMN flow direction, PMN adhesion did
not change (results not shown).
|
| Discussion |
|---|
|
|
|---|
Recent reports have shown that PMNs minimally adhere to injured vessel wall under flow conditions. The presence of platelets at these surfaces appears to be essential before PMN adhesion can take place. Platelet-associated (P-) selectin is critical for an initial slowing down or rolling interaction. Static leukocyte adhesion follows the interaction of ß2-integrins on leukocytes12 13 with platelet-associated ligands as fibrinogen bound to platelet GPIIbIIIa and ICAM-2.8 9 Also fibrin generated by the coagulation cascade and various matrix proteins are ligands for integrins.10 11
So far, only surfaces with nearly confluent coverage (>80%) of predominantly spread platelets were used to study the role of platelet-associated ligands in PMN adhesion. The influence of different platelet coverage and platelet activation on PMN adhesion, however, was not investigated. We therefore studied PMN adhesion on varying platelet coverage and on platelet aggregates. Moreover, we wanted to see whether inhibition of platelet aggregate formation and activation might be a tool to influence the subsequent inflammatory response. In a well-defined perfusion setup, we exposed different models of vessel wall damage to flowing blood, resulting in varying amounts of platelet coverage and activation.
Our experiments show a clear correlation between platelet coverage <15% and subsequent PMN localization. Under these conditions, we observe a characteristic hopping of PMNs from platelet to platelet. At platelet coverage >15%, PMNs are able to roll continuously. Although PMN rolling velocities decrease with increasing platelet coverage, the total PMN adhesion barely increases. The most likely explanation for our results is that a minimal presence of platelet-associated P-selectin enables a continuous rolling interaction, which is necessary before firm and integrin-dependent adhesion can occur. In accordance, we found a comparable effect of platelet coverage on monocyte adhesion.24 More platelets and thus P-selectin presence only lowers rolling velocity. Lawrence et al25 reported a similar decrease in rolling velocity when more purified P-selectin was coated on coverslips. The fact that total adhesion is scarcely affected by platelet coverage >15% suggests that platelets do not support integrinligand interactions substantially better than the ECM in between. The experiments with purified matrix proteins are consistent with the data obtained with ECM: PMN adhesion is only compromised at platelet coverage <15% (on Fn).
The lower PMN rolling velocity on platelets on FbM is not likely to be caused by increased platelet activation and P-selectin expression because even thrombin was not able to cause this. More efficient integrinligand interactions on FbM compared with ECM offers a better explanation. In accordance we showed earlier that PMNs also roll more slowly on platelets with fibrin in between than on platelets on ECM.26 Rolling velocity at fibrinogen also tended to be lower; however, significance was not reached.
Exposure of injured vessel wall in vivo to flowing blood will within minutes lead to platelet coverage >15%. Very few platelets at microlesions between endothelial cells, however, will mimic the conditions of our low-coverage experiments. In accordance, Kirton et al27 showed that low platelet adhesion supported PMN adhesion.
Our last goal was to determine whether PMN adhesion was influenced by the activation state of the platelets that were adherent. If the expression of P-selectin should change with this, one would expect parallel changes in PMN rolling velocity as were seen with varying amounts of platelet coverage. Thrombin was chosen as the strong coagulation-dependent platelet stimulus; indomethacin was chosen as a clinically important inhibitor of platelet aggregation. Both had no influence on platelet coverage. In this way, coverage-mediated effects on subsequent PMN adhesion were excluded. Additional platelet activation by thrombin or the aggregates at collagen surfaces changed neither PMN adhesion nor rolling velocity. Inhibition of platelet aggregate formation with indomethacin also had no influence. Hence, we conclude that P-selectin expression on adherent platelets is near maximal and not changed by additional platelet activation or inhibition. Interestingly, rheological differences between platelet aggregates and spread platelets did not influence PMN adhesion. This was clear from the experiments in which the elongated aggregates were turned 90 degrees to the PMN flow direction.
In conclusion, approximately 15% of platelet coverageno matter whether this coverage consists of spread platelets or platelet aggregatesoffers an optimal P-selectin-rich substrate for PMN adhesion. An adhering platelet expresses maximal P-selectin, because additional stimulation or inhibition of these platelets does not change PMN adhesion. An increase in the density of platelet-associated adhesion receptors can result in slower PMN rolling, but this is only obtained by increasing the platelet coverage. Our results indicate that minimal platelet presence, for example at microlesions of the vessel wall, strongly supports leukocyte adhesion. Inhibition of virtually all plateletvessel wall interactions will be necessary to influence this platelet-induced inflammatory response.
| Acknowledgments |
|---|
Received March 9, 1993; accepted September 10, 1998.
| References |
|---|
|
|
|---|
2.
Yeo EL, Sheppard JA, Feuerstein IA. Role of P-selectin
and leukocyte activation in polymorphonuclear cell adhesion to
surface adherent activated platelets under physiologic
shear conditions (an injury vessel wall model). Blood. 1994;83:24982507.
3.
Kuijper PHM, Gallardo Torres HI, van der Linden
JAM, Lammers J-WJ, Sixma JJ, Koenderman L, Zwaginga JJ.
Platelet-dependent primary hemostasis promotes selectin- and
integrin-mediated neutrophil adhesion to damaged
endothelium under flow conditions. Blood. 1996;87:32713281.
4. Palabrica TM, Lobb RR, Furie BC, Aronovitz M, Benjamin CD, Hsu YM, Sajer SA, Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 1992;359:848851.[Medline] [Order article via Infotrieve]
5. Marcus AJ, Safier LB, Ullman HL, Islam LN, Broekman MJ, Falck JR, Fischer S, von Schacky S. Platelet-neutrophil interactions in the eicosanoid pathway. Adv Exp Med Biol. 1988;243:3136.[Medline] [Order article via Infotrieve]
6. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest. 1988;58:249261.[Medline] [Order article via Infotrieve]
7.
Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer
TA. Neutrophil rolling, arrest, and transmigration across
activated, surface-adherent platelets via sequential action
of P-selectin and the ß2-integrin
CD11b/CD18. Blood. 1996;88:146157.
8. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest. 1997;100:20852093.[Medline] [Order article via Infotrieve]
9. Kuijper PHM, Gallardo Torres HI, van der Linden JAM, Lammers J-WJ, Sixma JJ, Koenderman L, Zwaginga JJ. Fibrinogen promotes MAC-1-induced firm attachment of neutrophils to immobilized platelets. Thromb Haemost. 1997;7:S600. Abstract.
10. Akiyama SK, Nagata K, Yamada KM. Cell surface receptors for extracellular matrix components. Biochim Biophys Acta. 1990;1031:91110.[Medline] [Order article via Infotrieve]
11. Hemler ME. VLA proteins in the integrin family: structures, functions and their role on leukocytes. Ann Rev Immunol. 1990;8:365400.[Medline] [Order article via Infotrieve]
12. Gahmberg CG. Leukocyte adhesion: CD11/CD18 integrins and intercellular adhesion molecules. Cell Biol. 1997;9:643650.
13. Ruoslahti E. Integrins. J Clin Invest.. 1991;87:15.
14. Sixma JJ, Pronk A, Nievelstein PFEM, Zwaginga JJ, Hindriks G, Tijburg P, Banga JD, de Groot PG. Platelet adhesion to extracellular matrices of cultured cells. In: Ruggeri ZM, Fulcher CA, Ware J, eds. Progress in Vascular Biology, Hemostasis and Thrombosis. New York, NY: Academy of Sciences; 1991:181192.
15. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical cord veins: identification of morphology and immunologic criteria. J Clin Invest. 1973;52:27452756.
16. Willems C, Astaldi GCB, de Groot PhG, Janssen MC, Gonsalves MD, Zeylemaker WP, van Mourik JA. Media conditioned by cultured human vascular endothelial cells inhibit the growth of vascular smooth muscle cells. Exp Cell Res. 1982;139:191197.[Medline] [Order article via Infotrieve]
17. Loesberg C, Gonsalvez MD, Zandbergen J, Willems C, van Aken WG, Stel HV, van Mourik JA, de Groot PhG. The effect of calcium on the secretion of factor VIII-related antigen by cultured human endothelial cells. Biochim Biophys Acta. 1983;763:160168.[Medline] [Order article via Infotrieve]
18.
Nievelstein PFEM, de Groot PG, D'Alessio P, Heynen
HFG, Orlando E, Sixma JJ. Platelet adhesion to vascular cells, the
matrices of cultured fibroblasts as model to study the role of
exogenous von Willebrand factor in platelet adhesion.
Arteriosclerosis. 1990;10:462469.
19. Sakariassen KS, Aarts PAMM, de Groot PhG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components. J Lab Clin Med. 1983;102:522535.[Medline] [Order article via Infotrieve]
20. Houdijk WPM, Sakriassen KS, Nievelstein PFEM, Sixma JJ. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III. J Clin Invest. 1985;75:531540.
21. Koenderman L, Kok PTM, Hamelink ML, Verhoeven AJ, Bruijnzeel PLB. An improved method for the isolation of eosinophilic granulocytes from peripheral blood of normal individuals. J Leukoc Biol. 1988;44:7986.[Abstract]
22. Sixma JJ, Wester JJ. The hemostatic plug. Semin Haematol. 1977;14:265299.[Medline] [Order article via Infotrieve]
23. Nievelstein PFEM, de Groot PhG. Interaction of blood platelets with the vessel wall. Haemostasis. 1988;18:342359.[Medline] [Order article via Infotrieve]
24. Kuijper HM, Gallardo Torre HI, Houben MJ, Lammers J-WJ, Zwaginga JJ, Koenderman L. P-selectin and Mac-1 mediate monocyte rolling and adhesion to ECM-bound platelets under flow conditions. J Leukoc Biol.. 1998;64:467473.[Abstract]
25. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell. 1991;65:859873.[Medline] [Order article via Infotrieve]
26.
Kuijper PHM, Gallardo Torres HI, Lammers J-WJ, Sixma
JJ, Koenderman L, Zwaginga JJ. Platelet- and
fibrin-depositions at the damaged vessel wall: cooperative substrates
for neutrophil adhesion under flow conditions. Blood. 1997;89:166175.
27. Kirton CM, Nash GB. Platelets can promote the capture and immobilisation of flowing neutrophils on confluent endothelial cell surface. Thromb Haemost. 1997;7:S600. Abstract.
This article has been cited by other articles:
![]() |
N. Maugeri, P. Rovere-Querini, V. Evangelista, C. Covino, A. Capobianco, M. T. S. Bertilaccio, A. Piccoli, L. Totani, D. Cianflone, A. Maseri, et al. Neutrophils phagocytose activated platelets in vivo: a phosphatidylserine, P-selectin, and {beta}2 integrin-dependent cell clearance program Blood, May 21, 2009; 113(21): 5254 - 5265. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. N. Morrell, K. Murata, A. M. Swaim, E. Mason, T. V. Martin, L. E. Thompson, M. Ballard, K. Fox-Talbot, B. Wasowska, and W. M. Baldwin III In Vivo Platelet-Endothelial Cell Interactions in Response to Major Histocompatibility Complex Alloantibody Circ. Res., April 11, 2008; 102(7): 777 - 785. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schulz, A. Schafer, M. Stolla, S. Kerstan, M. Lorenz, M.-L. von Bruhl, M. Schiemann, J. Bauersachs, T. Gloe, D. H. Busch, et al. Chemokine Fractalkine Mediates Leukocyte Recruitment to Inflammatory Endothelial Cells in Flowing Whole Blood: A Critical Role for P-Selectin Expressed on Activated Platelets Circulation, August 14, 2007; 116(7): 764 - 773. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.C. de Boer, C. Verseyden, L.H. Ulfman, J.J. Zwaginga, I. Bot, E.A. Biessen, T.J. Rabelink, and A.J. van Zonneveld Fibrin and Activated Platelets Cooperatively Guide Stem Cells to a Vascular Injury and Promote Differentiation Towards an Endothelial Cell Phenotype Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1653 - 1659. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Fontaine, Z. Touat, E. M. Mtairag, R. Vranckx, L. Louedec, X. Houard, B. Andreassian, U. Sebbag, T. Palombi, M.-P. Jacob, et al. Role of Leukocyte Elastase in Preventing Cellular Re-Colonization of the Mural Thrombus Am. J. Pathol., June 1, 2004; 164(6): 2077 - 2087. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Phillips, K. G. Barringhaus, J. M. Sanders, S. E. Hesselbacher, A. C. Czarnik, D. Manka, D. Vestweber, K. Ley, and I. J. Sarembock Single Injection of P-Selectin or P-Selectin Glycoprotein Ligand-1 Monoclonal Antibody Blocks Neointima Formation After Arterial Injury in Apolipoprotein E-Deficient Mice Circulation, May 6, 2003; 107(17): 2244 - 2249. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nishijima, J. Kiryu, A. Tsujikawa, M. Honjo, A. Nonaka, K. Yamashiro, H. Kamizuru, Y. Ieki, H. Tanihara, Y. Honda, et al. Inhibitory Effects of Antithrombin III on Interactions between Blood Cells and Endothelial Cells during Retinal Ischemia-Reperfusion Injury Invest. Ophthalmol. Vis. Sci., January 1, 2003; 44(1): 332 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Manka, R. G. Collins, K. Ley, A. L. Beaudet, and I. J. Sarembock Absence of P-Selectin, but Not Intercellular Adhesion Molecule-1, Attenuates Neointimal Growth After Arterial Injury in Apolipoprotein E-Deficient Mice Circulation, February 20, 2001; 103(7): 1000 - 1005. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |